TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01964911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaïne
Description: The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days).
Study: NCT03111654

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Compare the risk of a vascular event
Description: Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Compare the risk of a vascular event
Description: Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events.
Study: NCT04619056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEB-01 membrane loaded with SN-38
Description: CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEB-01 membrane loaded with SN-38
Description: CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEB-01 membrane loaded with SN-38
Description: CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
Study: NCT01265446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 8mg + CPC 2mg
Description: one single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1mg + CPC 2mg
Description: one single dose
Study: NCT02462577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: local instillation of morphine to surgical wound
Description: comparison between different drug doses effects on pain
Study: NCT00812045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: Oral tablet, 75 mg twice daily during 4 weeks
Study: NCT02462577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local instillation of morphine to surgical wound
Description: comparison between different drug doses effects on pain
Study: NCT00812045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02462577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local instillation of morphine to surgical wound
Description: comparison between different drug doses effects on pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local instillation of morphine to surgical wound
Description: comparison between different drug doses effects on pain
Study: NCT00830011

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: Ten sessions of manualized CBT delivered by a PhD level psychologist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical care
Description: any care recommended by physician for treatment of diabetic neuropathy including medication.
Study: NCT02550418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Study: NCT00382499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Intravenous Infusion
Description: 1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
Study: NCT00072982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: borage seed oil
Description: Borage oil 13 capsules divided doses daily for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination fish oil and borage seed oil
Description: Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
Study: NCT02806206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
Study: NCT02026050

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular dexamethasone
Description: 2ml 8 mg dexamethasone administration for intraarticular

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene dexamethasone
Description: 2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: serum phsyologic
Description: interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
Study: NCT01719614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
Study: NCT02519374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (including Maltodextrin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROMITOR® (including Maltodextrin)
Description: Investigational product dose 1
Study: NCT00557154

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard technique for venipuncture
Description: routine equipment
Study: NCT02618200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D prostate ultrasound
Study: NCT06155123

Intervention type: DRUG
Intervention: Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)
Description: Monthly or quarterly mAbs administration for a year
Study: NCT02519374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROMITOR® (including Maltodextrin)
Description: Investigational product dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROMITOR® (including Maltodextrin)
Description: Investigational product dose 3
Study: NCT00655629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT (STAXYN, BAY38-9456)
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
Study: NCT01722019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tulip fiber
Description: Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VNUS closure fast
Description: Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
Study: NCT00620594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study: NCT04533321

Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
Study: NCT02771717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort)
Description: Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - dummy inhaler
Description: Placebo - dummy inhaler to be taken 1 puff twice daily.
Study: NCT04327791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir
Description: administered PO once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: administered PO once
Study: NCT01216683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT00600210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions.
Study: NCT03291717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging Community Gaps Photovoice (BCGP)
Description: Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
Study: NCT05246800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured 8-week mHealth mindfulness program
Description: The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
Study: NCT00108771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZR-02-01 Fentanyl Transdermal Matrix Patch
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
Study: NCT04243993

Intervention type: OTHER
Group type: OTHER
Intervention: Calcium silicate cement
Description: Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Calcium silicate cement
Description: Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
Study: NCT02466932

Intervention type: DEVICE
Intervention: Galilei Dual-Scheimpflug Analyzer
Description: Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
Study: NCT03335774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
Description: One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) Suppository (Nivagen)
Description: One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
Study: NCT00491491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibritumomab tiuxetan
Description: 0.4 mCi/kg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BEAM chemotherapy and autologous stem-cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BEAM chemotherapy and autologous stem-cell transplantation
Study: NCT00125957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wellbutrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wellbutrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00557999

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Application of mechanical ventilation weaning protocol
Description: Application protocol for 8 months in experimental group

Intervention type: OTHER
Group type: OTHER
Intervention: Application of mechanical ventilation weaning protocol
Description: Application protocol for 8 months in experimental group
Study: NCT00988013

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (3Gy)
Description: Patients will receive 3Gy per day for 1 day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (6Gy)
Description: Patients will receive 3Gy per day for 2 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (9Gy)
Description: Patients will receive 3Gy per day for 3 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (12Gy)
Description: Patients will receive 3Gy per day for 4 days.
Study: NCT00305435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim (AMG-531)
Description: Romiplostim (AMG-531)
Study: NCT04005157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWA
Description: Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
Study: NCT02924493

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet low in fermentable carbohydrates (low FODMAP diet)
Description: The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in fermentable carbohydrates (low FODMAP diet)
Description: The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
Study: NCT03832335

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of aniseikonia tolerance
Description: Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of aniseikonia tolerance
Description: Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
Study: NCT05173909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS closed-loop target controlled infusion
Description: BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS closed-loop target controlled infusion
Description: BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol
Study: NCT03178604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic massage
Description: It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham massage
Description: This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
Study: NCT03652935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Series
Description: This is an active comparator condition that consists of 8 weekly classes related to health.
Study: NCT00620594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study: NCT04634149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days
Study: NCT00884234

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001 (Botulinum Toxin Type A Topical Gel)
Description: Two sequential doses of RT001 at Baseline (Day 0) and Week 2
Study: NCT02140034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive Peritoneal Lavage
Study: NCT03213808

Intervention type: OTHER
Intervention: No intervention: analysis of health data from patients with
Description: No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM

Intervention type: OTHER
Intervention: No intervention: analysis of health data from patients with
Description: No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM